Lilly’s Taltz® (ixekizumab) receives U.S. FDA approval for the treatment of active psoriatic arthritis
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA).1 Taltz was first approved...
Read More
